SuperworthNeuraxis, INC NRXS
- Market cap
- $92.9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 17.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $5.3M
- +65% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- not a meaningful number
Neuraxis, INC trades at 17.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $5.3M over the last twelve months, up 65% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $477.5K | n/a | $646.6K−20% | $611.5K−5% | $666.6K+40% | $761.2K | $895.7K+39% | $894.1K+46% | $811.4K+22% | $968.1K+27% | $1.6M+80% | $1.9M+116% | |
| Cost of revenue | $67.3K | n/a | $75.1K−22% | $73.5K+8% | $97K+44% | $105.1K | $139.5K+86% | $146.6K+100% | $135.5K+40% | $141.7K+35% | $218.4K+57% | $272.6K+86% |
| Gross profit | $410.2K | n/a | $571.6K−19% | $538K−7% | $569.6K+39% | $656.1K | $756.2K+32% | $747.4K+39% | $675.9K+19% | $826.5K+26% | $1.4M+84% | $1.7M+122% |
| R&D | $45K | n/a | $5.6K−67% | $54.3K−51% | $126.2K+181% | $138.4K | $117.9K+2016% | $115.2K+112% | $130.8K+4% | $146.2K+6% | $99.6K−16% | $274.3K+138% |
| SG&A | $3.4M | n/a | $2.4M+51% | $2.7M+70% | $2.1M−38% | $2M | $2.9M+22% | $2.4M−13% | $2.6M+26% | $2.4M+21% | $3M+3% | $3.5M+49% |
| −$3M | n/a | −$1.8M+104% | −$2.2M+98% | −$1.7M−45% | −$1.5M | −$2.3M+25% | −$1.7M−22% | −$2.1M+27% | −$1.7M+17% | −$1.7M−24% | −$2.1M+24% | |
| Interest expense | $102.6K | n/a | $26.6K−84% | $80.7K−59% | $64.7K−37% | $2.4K | $2.2K−92% | $13.4K−83% | $29.7K−54% | $28.6K+1096% | $26.2K+1071% | $19.8K+47% |
| Net income | −$8.6M | −$1.6M | −$2.1M−2% | −$2.9M+31% | −$1.8M−80% | −$1.4M−9% | −$2.3M+8% | −$1.7M−42% | −$2.1M+21% | −$1.7M+18% | −$1.8M−23% | −$2.1M+23% |
| −$2.38 | −$0.30 | −$0.32−73% | −$0.42−65% | −$0.25−90% | −$0.22−27% | −$0.33+3% | −$0.22−48% | −$0.24−4% | −$0.18−18% | −$0.18−46% | −$0.19−14% | |
| 3.6M | 5.3M | 6.6M+227% | 6.9M+246% | 7.2M+98% | 7.3M+36% | 7.5M+14% | 8.5M+23% | 9.9M+38% | 10.6M+46% | 10.9M+47% | 12.1M+42% |
Revenue: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
R&D: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
SG&A: Q1 FY22: 6 months less the 3 months printed beside them.
Operating income: Q1 FY22: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY22: 6 months less the 3 months printed beside them.
Net income: Q1 FY22: 6 months less the 3 months printed beside them.
EPS, diluted: 5 periods, Q1 FY22 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY22 and Q1 FY23: share-days: the 6-month average less the second quarter's. 3 periods, Q4 FY23 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Neuraxis, INC's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| NRXSNeuraxis, INC | $92.9M | n/m | n/a | 17.5× | +65% | n/m | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ELMDElectromed | $220.6M | 20.1× | 29.0× | 3.0× | +15% | 15.3% | |
| Peer median | $94M | 12.8× | 18.1× | 1.4× | +7% | 6.8% |
More on Neuraxis, INC
Each number over time
Its groups
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .